The history behind the discovery, research, and treatment of hemophilia is as complex and intriguing as the disease itself. A ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Discover how hemophilia A affects blood clotting, its genetic patterns, warning signs, advanced treatment options, and lifestyle modifications Skip to content News ...

Hemophilia A is a genetic disease marked by a deficiency or ... the efficacy of Hemlibra in reducing bleeding episodes in ...

Hemophilia is a rare genetic condition that keeps your blood from clotting, leading to bleeding problems. Bleeding can happen at any time (spontaneous) or as a result of trauma (injury, cut, or fall).

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of ...

Hemophilia B is a rare X-chromosome-linked bleeding disorder caused by mutations in ... “The results of this important study are a perfect example of how UCL research and innovation can ...

The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci) injection for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric ...

Pfizer’s hemophilia A gene therapy reduced annualized bleeding rates in a Phase 3 clinical trial, setting the stage for discussions with regulators. However, the market for such one-time ...

For the study, researchers dosed 75 patients (mean age, 32.3 [19-59]; 100% men, 74.7% White and 18.7% Asian,) with hemophilia A with giroctocogene fitelparvovec, a hepatocyte-directed recombinant ...

Pfizer got Beqvez in 2014 from Spark Therapeutics. The gene therapy biotech was later acquired by Roche, which has had its own struggles with the modality in hemophilia.. With its Sangamo ...